MedPath

Oak Hill Bio and Chiesi Group Expand OHB-607 Trial to Europe for BPD Prevention in Premature Infants

• Oak Hill Bio and Chiesi Group have enrolled the first European patient in a Phase IIb trial of OHB-607 for bronchopulmonary dysplasia (BPD) prevention. • The trial is a multi-center, randomized study comparing OHB-607 against standard neonatal care in infants born between 23 and 28 weeks of gestation. • OHB-607, a recombinant human insulin-like growth factor-1 (IGF-1), aims to support vital organ development in premature infants via continuous intravenous infusion. • The study's primary endpoint is reducing severe BPD incidence or death by 36 weeks postmenstrual age, with secondary endpoints assessing respiratory support, neurodevelopment, and prematurity complications.

Oak Hill Bio and Chiesi Group have extended their Phase IIb clinical trial of OHB-607 to Europe, enrolling the first European patient. This collaborative effort aims to prevent bronchopulmonary dysplasia (BPD) and other prematurity-related complications in extremely premature infants.
The open-label, multi-center, randomized, two-arm trial will evaluate OHB-607's efficacy against standard neonatal care in infants born between 23 and 28 weeks of gestation. Having commenced in the US in May 2024, the trial now includes sites in Europe and Japan, targeting a total enrollment of at least 105 infants across countries such as Germany, Finland, Ireland, Netherlands, Italy, Portugal, Spain, and the UK.

OHB-607: Mechanism and Administration

OHB-607 is a recombinant form of human insulin-like growth factor-1 (IGF-1), complexed with its primary binding protein. It is designed to bolster the development of critical organs in premature infants. The drug will be administered via continuous intravenous infusion starting 24 hours after birth and continuing until the infant reaches 30 weeks postmenstrual age, in conjunction with standard care tailored to each infant's specific needs.

Trial Endpoints and Assessments

The trial's primary endpoint is to assess the reduction in severe BPD incidence or death by 36 weeks postmenstrual age. Secondary endpoints include evaluating the impact of OHB-607 on weaning from respiratory support by 12 months corrected age, neurodevelopmental outcomes, and the incidence of other prematurity complications, such as retinopathy of prematurity and intraventricular hemorrhage. BPD severity will be graded using a modified score from the National Institute of Child Health and Human Development (NICHD).

Leadership Perspective

Chiesi Group global research and development executive vice-president Diego Ardigò stated, "The restart of this study marks a significant milestone highlighting the shared commitment of Chiesi and Oak Hill Bio to advance solutions for the vulnerable group of extremely premature infants, now including patients from Europe."
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

MBX Biosciences' MBX 1416 Shows Promise in Phase 1 Trial for Post-Bariatric Hypoglycemia

MBX Biosciences announced positive topline results from its Phase 1 trial of MBX 1416 in healthy volunteers, indicating a favorable safety profile.
The trial supports once-weekly dosing of MBX 1416, with a median half-life of approximately 90 hours observed in the multiple ascending dose cohort.

Interius BioTherapeutics' INT2104 In Vivo CAR-T Therapy Trial Expands to Europe

Interius BioTherapeutics received approval from the Paul Ehrlich Institute in Germany to expand its Phase 1 INVISE trial of INT2104 to Europe.
INT2104 is a first-in-class in vivo CAR gene therapy targeting CD20-positive B cells for treating B-cell malignancies.

BrainChild Bio Advances BCB-276 CAR T-cell Therapy for DIPG Following FDA Meeting

BrainChild Bio is set to advance BCB-276, an autologous CAR T-cell therapy, into a pivotal Phase 2 trial for diffuse intrinsic pontine glioma (DIPG).
The FDA has aligned with BrainChild Bio on a clinical plan to potentially accelerate the Biologics License Application submission for BCB-276.

Arbor Biotechnologies' ABO-101 Receives FDA Clearance for Phase 1/2 Trial in Primary Hyperoxaluria Type 1

Arbor Biotechnologies' ABO-101, a CRISPR-based gene editing therapy, has been cleared by the FDA for a Phase 1/2 clinical trial in primary hyperoxaluria type 1 (PH1).
The redePHine trial will evaluate ABO-101's safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in adult and pediatric patients with PH1.

Avidity Biosciences' Del-brax Trial Enrolls New Cohort for Accelerated FSHD Approval

Avidity Biosciences is enrolling a new patient cohort in its Phase 1/2 FORTITUDE trial to evaluate del-brax's impact on FSHD biomarkers.
The trial aims to gather data supporting accelerated approval of del-brax, a potential disease-modifying therapy targeting the root cause of FSHD.

Bavarian Nordic Initiates Phase II Trial of Mpox Vaccine in Toddlers

Bavarian Nordic has commenced a Phase II clinical trial to assess the safety and immunogenicity of its MVA-BN mpox vaccine in children aged 2-11 years.
The trial, partly funded by CEPI, aims to expand the vaccine's approval label to include younger children, addressing a critical gap in mpox prevention.

Bavarian Nordic's MVA-BN Mpox/Smallpox Vaccine Trial Enrolls First Children

Bavarian Nordic has initiated a clinical study of its MVA-BN mpox/smallpox vaccine in children aged 2 to 11 years, with the first vaccinations administered.
The study, involving 460 participants, will assess the vaccine's safety and immunogenicity in children compared to adults, potentially supporting label expansion.

Bavarian Nordic Initiates Clinical Trial of Mpox Vaccine in Young Children

Bavarian Nordic has begun a clinical study to assess its MVA-BN mpox vaccine in children aged 2-11 years, following approvals for adolescent use.
The trial, enrolling participants in the Democratic Republic of Congo and Uganda, will evaluate the vaccine's safety and immunogenicity compared to adults.

BIAL Doses First Patient in Phase 2 Trial of BIA 28-6156 for GBA-Related Parkinson's Disease

BIAL R&D has dosed the first patient in the Phase 2 ACTIVATE trial (NCT05819359) to evaluate BIA 28-6156 for Parkinson's disease patients with GBA1 gene mutations.
The ACTIVATE trial is a randomized, double-blind, placebo-controlled study assessing the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156 at two fixed dose levels.

BIAL R&D Doses First Patient in Phase 2 Trial of BIA 28-6156 for Parkinson's Disease with GBA1 Mutation

BIAL R&D has dosed the first patient in its Phase 2 ACTIVATE study, evaluating BIA 28-6156 for Parkinson's disease patients with a GBA1 gene mutation.
The ACTIVATE study is a multicenter, randomized, double-blind, placebo-controlled trial assessing the efficacy, safety, and tolerability of BIA 28-6156 at two fixed dose levels.

Reference News

[1]
Oak Hill Bio and Chiesi's OHB-607 trial enrols first European subject for BPD prevention
clinicaltrialsarena.com · Nov 4, 2024

Oak Hill Bio and Chiesi Group enrolled the first European patient in a Phase IIb trial for OHB-607, a drug to prevent br...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy